Because of poor compliance, 25% of all patients who are prescribed medicines derive no clinical benefit whatsoever.
Because of poor compliance, 25% of all patients who are prescribed medicines derive no clinical benefit whatsoever. As a result, pharmaceutical companies bear a drastic fall in revenues. AXA Assistance, experts in delivering/ leading providers of patient communication programmes, can share more than 8 years' experience in tailoring and managing successful compliance programmes.
As part of the AXA Global Group and one of the world?s top 20 companies, our service centres operate 24/7/365 out of over 30 sites around the world, offering tailored solutions to the pharmaceutical industry. We have supported many brands and, with an average increase in compliance of 30%, demonstrated a profitable return on investment.
Our core services include:
We believe that we have broken new ground by being the first company that truly meets all objectives of improving patient compliance. The principle aim is for patients and healthcare professionals to reap the benefits in turn deriving the maximum benefit for your brand. AXA Assistance ensure that the following is delivered as a minimum on all programmes implemented:
For further details contact:
Sunita Apte, Pharmaceutical Business Manger
Tel: +44 (0) 870 2406541
sunita.apte@axa-assistance.co.uk
Or visit www.axa-assistance.co.uk
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.